December 24, 2002 |
Genentech Inc. and Xoma Ltd. said they have asked U.S. regulators to approve Raptiva, an experimental treatment for moderate to severe psoriasis. Raptiva, a monoclonal antibody given weekly by injection, reduced psoriasis by at least 75% in some 61% of patients taking it for a year in clinical trials. Biogen Inc. is awaiting approval for its own experimental psoriasis treatment, Amevive. And Johnson & Johnson and Amgen Inc.
September 18, 2002 |
Genentech Inc. and Xoma Ltd. said Tuesday that their experimental drug for the skin disorder psoriasis cleared a major hurdle, increasing the likelihood that it will be approved for sale. Shares of Berkeley-based Xoma jumped 8% on the news, while stock in South San Francisco-based Genentech rose almost 3%. The market for psoriasis drugs is estimated at more than $1 billion in the United States and as much as $5 billion globally.
September 11, 2002 |
Biosite Inc., maker of medical diagnostic tests, resolved a licensing dispute with partner Xoma Ltd., which had alleged that Biosite infringed patents. The news sent shares of San Diego-based Biosite up 25%, or $5.22, to $25.77 on Nasdaq. Berkeley-based Xoma rose 36 cents to $5.91, also on Nasdaq. Biosite uses technology licensed from Xoma in manufacturing antibodies for tests to detect drug overdoses and heart disease.
June 29, 1999 |
Eye-care-products maker Allergan Inc. said it will pay up to $11 million to license a bacteria-fighting protein from biopharmaceuticals maker Xoma Ltd. for use in a family of eye-infection treatments. Xoma, which is based in Berkeley, said Irvine's Allergan will make a series of licensing payments as development and sales goals are reached. Allergan also will pay development costs for future products and royalties from sales of products containing the anti-bacterial protein, which Xoma will manufacture for Allergan.
September 25, 1997
Xoma Corp. said its Neuprex drug shows no safety problems, according to an analysis of its ongoing trial in patients with a rare and often fatal childhood disease. Berkeley-based Xoma said the results mean it will continue developing Neuprex. The drug is used in pediatric patients with severe meningococcemia, which strikes when the bacteria responsible for the more common meningitis disease invade a patient's bloodstream. Xoma shares fell 6 cents to close at $7.75 on Nasdaq.
October 29, 1991 |
Xoma Patent Upheld: Xoma Corp., a Berkeley biotechnology company, said a U.S. District Court in San Francisco upheld the validity of its patent covering the use of a genetically engineered treatment for septic shock syndrome, a bacterial infection that kills about 70,000 people in the United States annually. In April, 1990, after being granted a U.S. patent for the treatment, Xoma sued Centocor, a rival, alleging that the Malvern, Pa., company was copying its invention.